C12N 2760/18433
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2760/18433 (Use of viral protein as therapeutic agent other than vaccine) appears on 16 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 16
- Published applications
- 20
- Assignees
- 26
- Inventors
- 36
- Latest grant
- 12 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 3 |
| 2018 | 0 | 1 |
| 2019 | 2 | 3 |
| 2020 | 0 | 1 |
| 2021 | 1 | 1 |
| 2022 | 5 | 3 |
| 2023 | 0 | 3 |
| 2024 | 1 | 0 |
| 2025 | 2 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Targeting PD-L1 on tumor cells12 Aug 2025US 12,384,846 B2Mayo Foundation for Medical Education and Research
- RNA viruses for immunovirotherapy20 May 2025US 12,303,540 B2Deutsches Krebsforschung-Szentrum, Ruprecht-Karls-Universitat Heidelberg
- Engineered immunostimulatory bacterial strains and uses thereof18 Jun 2024US 12,012,600 B2Actym Therapeutics, Inc.
- DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of27 Dec 2022US 11,535,864 B2
- Targeting PD-L1 on tumor cells16 Aug 2022US 11,414,491 B2Mayo Foundation for Medical Education and Research
- Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of7 Sep 2023US 2023/0279429 A1
- Dna molecules producing custom designed replicating and non-replicating negative stranded rna viruses and uses there of31 Aug 2023US 2023/0272423 A1
- Combination antiviral therapy for measles19 Jan 2023US 2023/0014151 A1Cornell University
- Targeting pd-l1 on tumor cells15 Dec 2022US 2022/0396625 A1Mayo Foundation for Medical Education and Research
- Treatment of cancer using recall antigens delivered by attenuated bacteria28 Apr 2022US 2022/0125901 A1Albert Einstein College of Medicine
Most cited
By later US patents
- Methods and materials for treatment of rheumatoid arthritis19US 4,704,273 A1987
- Influenza virus inhibiting peptides5US 7,491,793 B2The Administrators of the Tulane Educational Fund · 2009
- Treatment of influenza virus infection4US 8,598,116 B2Educational Fund and Autoimmune Technologies, LLC · 2013
- Engineered immunostimulatory bacterial strains and uses thereof3US 11,242,528 B2Actym Therapeutics, Inc. · 2022
- Targeting PD-L1 on tumor cells3US 11,414,491 B2Mayo Foundation for Medical Education and Research · 2022